12/4
06:33 pm
acad
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality [Seeking Alpha]
Low
Report
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality [Seeking Alpha]
12/4
01:01 pm
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/3
09:42 am
acad
Acadia to pivot to Alzheimer's psychosis pipeline, accd to Wall Street analysts [Yahoo! Finance]
Low
Report
Acadia to pivot to Alzheimer's psychosis pipeline, accd to Wall Street analysts [Yahoo! Finance]
12/2
09:03 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $29.00 price target on by analysts at Mizuho.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $29.00 price target on by analysts at Mizuho.
11/20
04:30 pm
acad
Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference [Yahoo! Finance]
11/20
04:05 pm
acad
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
Low
Report
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
11/17
12:37 pm
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $33.00 to $31.00. They now have an "overweight" rating on the stock.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $33.00 to $31.00. They now have an "overweight" rating on the stock.
11/10
04:33 pm
acad
ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Medium
Report
ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/9
07:03 pm
acad
Is ACADIA's Raised Guidance and Acquisition Plans Reshaping the Investment Narrative for ACAD? [Yahoo! Finance]
Low
Report
Is ACADIA's Raised Guidance and Acquisition Plans Reshaping the Investment Narrative for ACAD? [Yahoo! Finance]
11/6
10:50 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at Royal Bank Of Canada from $34.00 to $32.00. They now have an "outperform" rating on the stock.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at Royal Bank Of Canada from $34.00 to $32.00. They now have an "outperform" rating on the stock.
11/6
08:10 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Needham & Company LLC from $28.00 to $29.00. They now have a "buy" rating on the stock.
Medium
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Needham & Company LLC from $28.00 to $29.00. They now have a "buy" rating on the stock.
11/6
04:37 am
acad
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/6
12:10 am
acad
ACADIA Pharmaceuticals Inc (ACAD) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... [Yahoo! Finance]
Low
Report
ACADIA Pharmaceuticals Inc (ACAD) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... [Yahoo! Finance]
11/5
04:05 pm
acad
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
Medium
Report
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
10/28
04:05 pm
acad
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Low
Report
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
10/28
10:00 am
acad
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
10/23
11:00 am
acad
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
10/22
03:41 pm
acad
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
10/21
09:20 am
acad
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Low
Report
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
10/21
09:20 am
acad
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Low
Report
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
10/21
08:03 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $33.00 price target on the stock.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $33.00 price target on the stock.
10/18
10:00 am
acad
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
10/15
04:05 pm
acad
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
Medium
Report
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
10/13
01:42 pm
acad
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
10/8
04:36 pm
acad
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD